TxCell is a biotech company developing innovative and personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for autoimmune diseases and severe chronic inflammatory diseases.
TxCell – antigen-specific Type 1 Treg cells
Type 1 Treg cells are naturally occurring blood cells specialized to induce tolerance against environmental foreign antigens. Type 1 Treg cells have been shown to prevent autoimmune and chronic inflammatory diseases in experimental animal models (arthritis, colitis, multiple sclerosis, etc…). TxCell’s technology is based on the immuno-modulatory properties of these peripheral blood antigen-specific Type 1 regulatory T cells (Ag-Treg). TxCell proprietary manufacturing process uses a single peripheral blood sample from a patient, where cells are educated ex-vivo to specifically recognize a chosen antigen. Ag-Tregs are mass produced and multiple doses of treatment are stored frozen. The product is administered to the patient by intravenous injection. When Ag-Treg cells are re-injected, they home to the site of inflammation where they are activated by the specific antigen. These Ag-Tregs then act by releasing locally immune suppressive factors, cell-cell contacts and cytotoxic activity to treat the inflammation. TxCell’s strategy is to target niche for which there are few or no treatment options. TxCell’s lead product candidate is Ovasaves. A phase I/IIa study in refractory Crohn’s Disease patients has been successfully completed and reported positive clinical efficacy and good tolerability. A phase IIb placebo controlled study is currently ongoing. TxCell’s second product candidate is Col-Treg, targeting Autoimmune Uveitis, a rare disease with very limited treatment options. A phase I/II proof of principle clinical trial will start soon.
Based in Sophia-Antipolis, TxCell is a biotechnology company founded in 2001 as a spin-off from the INSERM (Institut National de la Santé et de la Recherche Médicale). TxCell’s technology is based on the pioneering work of the founding scientist, who co-discovered in 1997 the type 1 regulatory T lymphocytes. Management Team is composed by Damian Marron (CEO), Miguel Forte, Arnaud Foussat, Raphael Flipo and Eric Pottier. Board of directors is composed by François Meyer, Marie-Laure Garrigues, Bernard Daugeras, Emmanuel Fiessinger, Marie Landel, Laurent Arthaud and Laurent Higueret. TxCell has been funded by private funds for a total of 36.8M€ invested through three rounds of financing by Bpifrance (Innobio), Seventure Partners, Auriga Partners, Innovation Capital and AXA Private Equity.
More about TxCell : www.txcell.com
TxCell – T cell immunotherapies – antigen specific regulatory T-cells – Ag-Tregs – antigen-specific Type 1 Treg cells – antigen-specific Type 1 Treg cell – antigen specific Type 1 Treg cells – antigen specific Type 1 Treg cell – Ovasaves – Col-Treg
TxCell – T cell immunotherapy – T-cell immunotherapies – T-cell immunotherapy – antigen specific regulatory T-cell – Ag-Treg – autoimmune diseases – severe chronic inflammatory diseases – autoimmune – chronic inflammatory disease – chronic inflammatory – Type 1 Treg cells – Type 1 Treg cell – arthritis – colitis – multiple sclerosis – immuno-modulatory – immune modulatory – Crohn’s Disease – Crohn – phase IIb placebo controlled study – Col Treg – autoimmune uveitis – autoimmune – uveitis – INSERM – Institut National de la Santé et de la Recherche Médicale – Damian Marron – Miguel Forte – Arnaud Foussat – Raphael Flipo – Eric Pottier – François Meyer – Marie-Laure Garrigues – Bernard Daugeras – Emmanuel Fiessinger – Marie Landel – Laurent Arthaud – Laurent Higueret – Bpifrance Innobio – Bpifrance – Innobio – Seventure Partners – Auriga Partners – Innovation Capital – AXA Private Equity